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Abstract
Current evidence suggests a multifactorial etiology to pelvic organ prolapse (POP), includ-
ing genetic predisposition. We conducted a genome-wide association study of POP in Afri-
can American (AA) and Hispanic (HP) women from theWomen’s Health Initiative Hormone
Therapy study. Cases were defined as any POP (grades 1–3) or moderate/severe POP
(grades 2–3), while controls had grade 0 POP. We performed race-specific multiple logistic
regression analyses between SNPs imputed to 1000 genomes in relation to POP (grade 0
vs 1–3; grade 0 vs 2–3) adjusting for age at diagnosis, body mass index, parity, and genetic
ancestry. There were 1274 controls and 1427 cases of any POP and 317 cases of moder-
ate/severe POP. Although none of the analyses reached genome-wide significance
(p<5x10-8), we noted variants in several loci that met p<10−6. In race-specific analysis of
grade 0 vs 2–3, intronic SNPs in the CPE gene (rs28573326, OR:2.14; 95% CI 1.62–2.83;
p = 1.0x10-7) were associated with POP in AAs, and SNPs in the gene AL132709.5
(rs1950626, OR:2.96; 95% CI 1.96–4.48, p = 2.6x10-7) were associated with POP in HPs.
Inverse variance fixed-effect meta-analysis of the race-specific results showed suggestive
signals for SNPs in the DPP6 gene (rs11243354, OR:1.36; p = 4.2x10-7) in the grade 0 vs
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1–3 analyses and for SNPs around PGBD5 (rs740494, OR:2.17; p = 8.6x10-7) and SHC3
(rs2209875, OR:0.60; p = 9.3x10-7) in the grade 0 vs 2–3 analyses. While we did not identify
genome-wide significant findings, we document several SNPs reaching suggestive statisti-
cal significance. Further interrogation of POP in larger minority samples is warranted.
Introduction
Pelvic organ prolapse (POP) is a highly prevalent condition associated with significant morbid-
ity that affects up to 40% of postmenopausal women [1], with 20% of women opting for surgi-
cal management by age 80 [2]. Although several risk factors for POP have been identified,
including age [3], race [4;5], parity [1;6] and obesity [1;7;8], the underlying pathophysiology of
POP remains unknown.
Epidemiologic studies have reported family history as a significant risk factor [9–11] and
familial forms of POP have been reported [12;13]. In addition, several candidate gene studies
[14–18] and one genome wide association study (GWAS) have identified promising single
nucleotide polymorphisms (SNPs) associated with POP [19]. A recently published genome-
wide linkage analysis provided evidence for two additional loci in relation to symptomatic POP
[20]. However, a majority of the existing studies have focused on women of European ancestry
and there are few validated loci known for POP [21].
Given the limitations in the current literature, the Women’s Health Initiative SNP Health
Associated Resources (SHARe) dataset provides a unique opportunity to explore the genetic
susceptibility to POP in minority women, as this dataset includes extensive phenotypic and
genotypic information on African American (AA) and Hispanic (HP) postmenopausal
women. Investigating the genetic epidemiology of POP in these populations is particularly
important, as epidemiologic data suggest that the risk for POP varies by race. Prior studies
have reported that AA women have the lowest risk [1;5], while white and Hispanic women
have the highest risks [1;5]. Thus, the objective of our study was to identify loci associated with
POP in AA and HP women using the Women’s Health Initiative-SHARe dataset.
Materials and Methods
Study Population
Data used in this study were obtained from AA and HP women who were enrolled in the
Women’s Health Initiative hormone therapy (HT) trial (registered in ClinicalTrials.gov; regis-
tration number: NCT00000611) and for whom genotyping data was available through Wom-
en’s Health Initiative-SHARe. The Women’s Health Initiative is a large prospective study
which recruited 161,861 post-menopausal women between 50–79 years of age from 40 clinical
centers throughout the US from 1993–1998. Eligible participants were enrolled to the observa-
tional study or one or more of the three clinical trials: HT, dietary modification and/or calcium
and Vitamin D supplementation trial [22]. Briefly, post-menopausal women who were unlikely
to move and had predicted survival for three or more years, who were not using hormone ther-
apy or were willing to stop, and who were currently not participating in any other clinical trial
were eligible to participate.
Information regarding demographics, clinical, behavioral characteristics, medical history,
and lifestyle/behavioral factors, among other risk factors, was obtained by standardized self-
administered questionnaires at baseline. Information regarding POP was ascertained through
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standardized pelvic exams performed on women participating in the Women’s Health Initia-
tive-HT trial. Baseline pelvic exams were performed using standardized procedures by a gyne-
cologist, experienced nurse, or physician assistant. Pelvic exams included an evaluation of the
presence of uterine prolapse, cystocele, and rectocele using Women’s Health Initiative Prolapse
Classification System (grades: 0, no prolapse; 1, prolapse in vagina; 2, prolapse to introitus; and
3, prolapse outside vagina). Examination for POP was performed in a supine lithotomy posi-
tion while participant was asked to perform the Valsalva maneuver. Annual pelvic exams were
also performed during follow-up physical exams with participants having between one to 10
visits. Further details regarding Women’s Health Initiative protocols and ascertainment for
Women’s Health Initiative have been previously described [23;24].
For this study, cases were defined as women with a cystocele, rectocoele, or uterine prolapse
of any severity (grades 1–3) at baseline or at one of the 10 follow-up visits. Since multiple
assessments of POP were available for women in this study, the first occurrence of a cystocele,
rectocele or uterine prolapse of any severity (grades 1–3) was coded as any POP, and the first
occurrence of a cystocele, rectocele or uterine prolapse of grade II or higher was coded as mod-
erate-severe POP. For women with multiple assessments of POP through time, the highest
grade of POP across visits was used as their POP status for the purposes of our analyses. Con-
trols were women who did not have any of the three forms of POP: rectocele, cystocele and
uterine prolapse (grade 0) at baseline or at follow-up visits when POP was assessed. Our pri-
mary analyses compared controls to women with any POP (grade 0 vs. grade 1–3) or moder-
ate/severe POP (grade 0 vs. grade 2–3). Variables examined in this study included age at
diagnosis and variables collected at baseline: age at baseline interview, parity, body mass index
(BMI), waist circumference, cigarette smoking history, prior hysterectomy, and menopausal
hormone use status. De-identified data were assessed through authorized and secure methods
after Institutional Review Board approval at Vanderbilt University and approval from the
Women’s Health Initiative, and the database of Genotypes and Phenotypes (dbGaP).
Genotyping
The Affymetrix Human SNP Array 6.0 (Affymetrix1, Inc Santa Clara, CA) was used for
genome wide SNP genotyping. Genomic DNA was quantitated via an ND-8000 spectropho-
tometer and DNA quality was evaluated via gel electrophoresis. The genomic DNA samples
were processed according to standard Affymetrix procedures for processing of the assay. The
data were processed for genotype calling using the Affymetrix1 Genotypic Console software
using the Birdseed calling algorithm version 2.0 (Affymetrix1, Inc., Santa Clara, CA) [25].
Quality Control (QC)
Data on 909,622 SNPs and 12,007 individuals were available prior to implementation of quality
control. 177 individuals were removed after excluding individuals with low genotyping quality
(<98%). 188 individuals with first degree or higher relatedness were identified using identity-
by-descent sharing from a random selection of 100,000 autosomal SNPs, and removed from
analysis. Finally, we removed 140 subjects with inconsistent reported versus genetically deter-
mined sex. This resulted in 8,180 AA and 3,322 HP women remaining after sample QC.
All SNPs were tested for deviation from Hardy-Weinberg equilibrium (HWE) using PLINK
software, stratified by race [26]. We excluded SNPs with HWE P10−6, low genotyping quality
(<98%), a minor allele frequency (MAF)< 0.01, non-autosomal SNPs, and SNPs that did not
map to a chromosomal position. Furthermore, we plotted the allele frequencies for the AA and
HP datasets against the allele frequencies corresponding to the African reference population
and American Indian reference population from the 1000 genomes build 37, respectively. We
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created these plots to identify and exclude SNPs which had discordant allele frequencies (abso-
lute value difference> 0.1) compared with their respective reference populations, and to
exclude palindromic SNPs with MAF> 0.4 for which the reference strand could not be deter-
mined easily. This resulted in a total of 777,060 SNPs in AAs and 730,985 SNPs in HPs avail-
able for imputation. Quality control procedures are detailed in Fig 1.
Imputation was conducted using IMPUTE2, using samples and genotypes that passed QC
and all 1000 genomes reference panels (build 37, 2013) to increase imputation accuracy
[27;28]. Imputation was limited to 1769 AAs and 932 HPs, as data on POP was limited to these
individuals. Prior to imputation, genotype data were phased using SHAPEIT software [29].
Analytic Sample
Of the 8180 AA and 3322 HP women with genetic data, 1,769 AA and 932 HP women had1
pelvic exams and thus contributed information on POP. Of the 1,769 AA and 932 HP women,
514 AA and 437 HP women had POP (considering any severity of rectocele, cystocele and uter-
ine prolapse) at baseline. During follow-up, 292 AA women and 184 HP women additionally
developed POP. Our final analytical sample included 793 grades 1–3 cases, 154 grades 2–3
cases, and 948 controls in AA women, and 606 grades 1–3 cases, 163 grades 2–3 cases, and 305
controls in HP women who had no missing data on important covariates such as age at diagno-
sis, body mass index, hysterectomy status and parity.
Population Stratification
In order to assess population stratification among AAs and HP samples multi-dimensional
scaling (MDS) was employed using PLINK software to estimate continuous axes of ancestry
[26]. The top four MDS components were extracted for AAs and HP groups individually and
used as covariates in SNP association analyses to adjust for potential confounding due to ances-
try. A plot of the top two MDS components from the sample data (AAs and HP), and the Inter-
national HapMap Project Phase 3 populations (ASW: African ancestry in Southwest USA;
Fig 1. The flow chart presents an overview of sample and SNP inclusion/exclusion during quality control.
doi:10.1371/journal.pone.0141647.g001
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MXL: Mexican ancestry from Los Angeles, CA; LWK: Luhya in Webuye, Kenya; MKK: Maasai
in Kinyawa, Kenya; YRI: Yoruban in Ibadan, Nigeria) was produced to visualize ancestral
genetic differences (S1 Fig).
Power
We performed power calculations a priori using the Quanto (Version 1.2.4) software. Assum-
ing a meta-analysis sample size of approximately 1400 cases, a genome-wide p-value threshold
of 5 x 10−8, an approximate 1:1 case to control ratio, a baseline prevalence of 40% and a log-
additive model for SNP effect, we estimated 80% power to detect minimum odds ratios of 1.48,
1.45, 1.43, and 1.42 for minor allele frequencies of 0.25, 0.30, 0.35 and 0.40, respectively.
Statistical Analyses
Participant and demographic characteristics were analyzed with two-sample t-tests assuming
unequal variance to compare between racial groups when variables were continuous, and Chi-
squared tests when variables were categorical using Stata, version 11 (StataCorp, College Sta-
tion, TX, USA).
The association between each genetic marker and POP status (binary) was assessed using
logistic regression stratified by race adjusting for established POP risk factors identified in the
literature including: age at POP ascertainment (continuous), BMI (continuous), parity (contin-
uous) and MDS-derived axes of ancestry (continuous) using SNPTEST software [30]. Interpre-
tation of analyses from logistic regression models were limited to genotyped and imputed
SNPs with a post-imputation information score of0.4, Hardy-Weinberg equilibrium P value
>1x10-8, and minor allele frequency>0.05. Quantile-quantile plots for SNP association analy-
ses for AA and HP subjects considering grade -0 vs. 1–3 and grade 0 vs. 2–3 POP are shown in
Fig 2. Manhattan plots for race/ethnicity specific analyses considering grade -0 vs. 1–3 and
grade 0 vs. 2–3 POP are shown in S2 Fig through S5 Fig. We then conducted inverse variance
weighted fixed-effect meta-analysis between AA and HP results using the PLINK software. We
resorted to using a fixed-effect meta-analysis technique instead of more sophisticated trans-
ethnic meta-analysis techniques such as new random-effect models [31] or MANTRA [32]
since only two independent datasets were available.
We performed several sensitivity analyses. We compared the results of six genome-wide sig-
nificant SNPs reported by a previous GWAS study on POP with our results [19]. In the
WHI-HT a large proportion of women had hysterectomy at baseline, with no indication for
the reason for hysterectomy and the possibility that some of these women may have had POP
previously could not be ruled out. Consequently, in the WHI-HT hysterectomy status was
inversely associated with POP. However, women without a uterus may still develop other
forms of POP such as rectocele and cystocele. In order to minimize the possibility that the asso-
ciations observed with SNPs were not directed by any potential bias introduced by this misclas-
sification, top hits (p< 10−5) from primary models were additionally adjusted for
hysterectomy status. We also performed logistic regression analyses by strata of hysterectomy
status for the top-SNPs from primary models. All p-values presented are two-sided.
Results
In this case-control study, the mean ages at diagnosis for AA and HP women were 62 and 60
years respectively (Table 1). Characteristics of AA and HP participants from this sub-study are
similar to those in the parent Women’s Health Initiative-HT study. Compared with HP
women, AA women were on average more likely to be older, have higher BMI (29.8 vs. 31.6),
more likely to be current smokers, and more likely to have had prior hysterectomy at baseline
GWAS of Pelvic Organ Prolapse among Minorities
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(40.7% vs. 57.7%). Advancing age, increasing BMI and parity were all associated with increased
odds of POP across all grades (S1 Table).Prior hysterectomy was inversely associated with POP
(OR: 0.24; 95% CI: 0.20, 0.29). HP women were approximately twice as likely as AA women to
have POP (S1 Table). The racial disparity in POP existed irrespective of hysterectomy status.
We first evaluated the relationships between SNPs and any severity of POP in AA and HP
populations separately using multiple logistic regression models adjusted for age at ascertain-
ment, BMI, parity and four MDS components of genetic ancestry (Table 2). While no SNPs
reached genome-wide significance, we noted those that reached a P value threshold of<10−6.
In analyses specific to AA women considering any POP, SNP rs7035589 (OR: 1.44; 95% CI:
1.25–1.65; P = 2.92x10-7), located near the gene ATP-binding cassette, subfamily-A (ABC1),
member 1 (ABCA1) had the smallest P value. Similarly, in analyses specific to HP women con-
sidering any POP, SNP rs144039930 (OR: 0.15; 95% CI: 0.07–0.31; P = 3.80x10-7) located in
the intronic region of gene ankyrin repeat and sterile alpha motif domain containing 4B
(ANKS4B) had the smallest P value. Regional association plots corresponding to these loci are
presented in Fig 3.
In addition to evaluating women with any POP, we also analyzed AA and HP women with
moderate-severe POP (grades 2–3), adjusting for the same variables described above (Table 3).
Again, in race-ethic stratified analyses, no loci reached genome-wide significance, but we iden-
tified SNPs in seven loci in the AA population and SNPs in three loci in the HP population
which were associated with grades 2–3 POP at a P value threshold of<1.00x10-6. In analyses
specific to AA women, the most significant SNP associated with moderate/severe POP was
SNP rs28573326 (OR: 2.14; 95% CI 1.62–2.83; P = 1.04x10-7) which is located in the intronic
Fig 2. Quantile-quantile (Q-Q) plot of association analysis results. Expected–log10 p values are on the
x-axis and the observed–log10 p values are on the y-axis. A) African Americans grade 0 vs. 1–3; B)
Hispanics grade 0 vs. 1–3; C) African Americans grade 0 vs. 2&3; D) Hispanics grade 0 vs. 2&3.
doi:10.1371/journal.pone.0141647.g002
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region of the carboxypeptidase E (CPE) gene. Similarly, in analyses specific to HP women we
found several SNPs in and around the gene AL132709.5 to be associated with grades 2–3 POP,
with rs1950626 (OR: 2.96; 95% CI: 1.96–4.48; P = 2.64x10-7) as the most significant SNP in the
region. Regional association plots for top loci from the grade 0 vs. 2–3 analyses are shown in
Fig 4. for AA subgroup and Fig 5. for HP subgroup. Race/ethnicity specific correlation plots for
top associated SNPs (P< 10−5) from analyses of either any POP or moderate/severe POP not
only showed that the effect size estimates were in the same direction, but that the magnitude of
the effect size was larger in the moderate/severe POP analyses than in the any POP analyses
(S6 Fig).
We then aggregated the signals from the AA and HP analyses by performing inverse vari-
ance weighted fixed effects meta-analysis for both definitions of POP (Table 4): any POP
Table 1. Demographic Characteristics of African American (AA) and Hispanic (HP) POP cases and controls from theWomen’s Health Initiative.
Continuous Variables AA (N = 1769) HP (N = 932)
Cases (806) Controls (963) Cases (621) Controls (311)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age at baseline (years) 61.84 (6.96) 61.13 (7.01) 59.62 (6.35) 59.62 (6.32)
Age at diagnosis (years)* 63.12 (7.09) 61.14 (7.01) 60.37 (6.45) 60.42 (6.43)
BMI (kg/m2)* 31.62 (6.18) 31.51 (6.44) 29.89 (5.27) 29.68 (5.89)
Waist Circumference (cm) 93.56 (13.03) 92.70 (13.35) 89.33 (11.87) 88.46 (12.55)
Categorical Variables N (%) N (%) N (%) N (%)
BMI
<25 kg/m2 100 (12.41) 143 (14.85) 107 (17.23) 65 (20.90)
25-<30 kg/m2 258 (32.01) 293 (30.43) 239 (38.49) 121 (38.91)
> = 30 kg/m2 446 (55.33) 521 (54.10) 274 (44.12) 122 (39.23)
Missing 2 (0.25) 6 (0.62) 1 (0.16) 3 (0.93)
Parity*
Nulliparous 81 (10.05) 163 (16.93) 39 (6.28) 31 (9.97)
1 91 (11.29) 149 (15.47) 44 (7.09) 32 (10.29)
2 181 (22.46) 211 (21.91) 115 (18.52) 63 (20.26)
3 143 (17.74) 171 (17.76) 109 (17.55) 66 (21.22)
4 107 (13.28) 99 (16.72) 119 (19.16) 44 (14.15)
5 192 (23.82) 161 (16.72) 184 (29.63) 72 (23.15)
Missing 11 (1.36) 9 (0.93) 11 (1.77) 3 (0.96)
Hysterectomy
No 463 (57.44) 286 (29.70) 452 (72.79) 101 (32.48)
Yes 343 (42.56) 677 (70.30) 169 (27.21) 210 (67.52)
Smoking status
Never 393 (48.76) 431 (44.76) 396 (63.77) 184 (59.16)
Past 298 (36.97) 361 (37.49) 162 (26.09) 98 (31.51)
Current 103 (12.78) 149 (15.47) 54 (8.70) 29 (9.32)
Missing 12 (1.49) 22 (2.28) 9 (1.45) 0 (0.00)
Hormone therapy use
Never 459 (56.95) 511 (53.06) 366 (58.94) 163 (52.41)
Past 281 (34.86) 362 (37.59) 184 (29.63) 113 (36.33)
Current 51 (6.33) 86 (8.93) 54 (8.70) 34 (10.93)
Missing 15 (1.86) 4 (0.42) 17 (2.74) 1 (0.32)
*Primary logistic regression models were adjusted for the following demographic variables: age at ascertainment, BMI (continuous) and parity continuous)
doi:10.1371/journal.pone.0141647.t001
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(grades 1–3) and moderate-severe POP (grades 2–3). Fixed effects meta-analysis of AA and HP
datasets for any severity of POP showed only one intronic SNP located in the DPP6 gene to be
associated with any POP at a P value threshold of<1x10-6 with similar effect sizes in both data-
sets: rs11243354 (Meta-analysis OR: 1.36; 5.22x10-7; I2 = 0). Meta-analysis of the AA and HP
datasets for moderate-severe POP (grades 2–3) showed a SNP near the PGBD5 gene (rs740494;
OR: 2.17; P = 8.61x10-7) to be associated with POP. A more detailed list of SNPs from indepen-
dent loci with P value threshold<10−5 for the any POP and moderate-severe POP analyses are
shown in S2 Table and S3 Table.
Table 2. Top genetic loci associated with any pelvic organ prolapse (grade 0 vs. 1–3) in African American (AA) and Hispanic (HP) women from the
Women’s Health Initiative.
SNP CHR BP On/Nearby Genes EA/RA EAF info OR 95% CI P
AA rs7035589 9 107752358 LOC101928579*,ABCA1 T/C 0.39 1.00 1.44 1.25–1.65 2.92x10-7
rs139563135 1 15633817 FHAD1* A/G 0.15 0.81 1.64 1.35–2.00 6.82x10-7
HP rs144039930 16 21252260 ANKS4B*,ZP2,CRYM T/C 0.05 0.68 0.15 0.07–0.31 3.80x10-7
rs10160713 11 96898237 LOC100131233,MAML2 T/A 0.06 0.77 0.22 0.12–0.40 9.51x10-7
CHR = Chromosome; SNP = Single Nucleotide Polymorphism; EA = Effect Allele; RA = Reference Allele
*SNP is on gene
EAF = Effect Allele Frequency for Controls; OR = Odds Ratio; CI = Confidence Interval; P = P-value from logistic regression; Logistic regression models
were adjusted for age at ascertainment, BMI (continuous), parity continuous) and 4 genetic ancestry components (continuous)
doi:10.1371/journal.pone.0141647.t002
Fig 3. Regional association plots showing–log10(p-values) against base-pair position for African
American (AA) (top) and Hispanic (HP) (bottom) women considering grade 0 vs. 1–3 analyses.
doi:10.1371/journal.pone.0141647.g003
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To evaluate the robustness of SNPs with the lowest P values in our study (P<10−6), we per-
formed several sensitivity analyses. To evaluate if there was more than one independent SNP
contributing to the signals in a given region, we regressed SNPs in the region while condition-
ing on the SNP with the smallest P value for that respective region. We did not identify any
additional SNPs that had signals<10−6 after conditional analyses. Furthermore, since women
who had previously had hysterectomy at baseline assessment were less likely to have/develop
POP, we reevaluated the top SNPs (P<10−5) from our original models while additionally
adjusting for hysterectomy status (S7 Fig). The effect estimates we observed from these models
Table 3. Top genetic loci associated with severe pelvic organ prolapse (grade 0 vs. 2–3) in African American (AA) and Hispanic (HP) women from
theWomen’s Health Initiative.
SNP CHR BP On/Nearby Gene EA/RA EAF info OR 95% CI P
rs28573326 4 166338328 CPE* G/A 0.29 0.97 2.14 1.62–2.83 1.04x10-7
rs9772809 8 42658181 THAP1,CHRNA6,CHRNB3 C/T 0.93 0.58 0.20 0.11–0.36 1.51x10-7
rs201058683 5 26876667 CDH9 AT/A 0.21 0.79 2.47 1.76–3.47 1.88x10-7
AA rs3850352 2 56255496 EFEMP1,MIR216-A,B,MIR217 C/T 0.82 0.95 0.42 0.31–0.59 2.91x10-7
rs7187140 16 16011680 FOPNL,ABCC1,MYH11 C/T 0.09 0.43 5.35 2.82–10.16 3.02x10-7
rs113872281 3 108653832 GUCA1C*,MORC1 G/T 0.17 0.98 2.27 1.65–3.14 6.27x10-7
rs73318770 8 74362915 STAU2* G/A 0.07 0.98 3.21 2.02–5.11 8.46x10-7
rs1950626 14 101373973 AL132709.5,MIR370,RTL1 G/A 0.79 0.94 2.96 1.96–4.48 2.64x10-7
HP rs10110287 8 21487130 GFRA2 T/C 0.08 0.78 3.69 2.20–6.18 7.05x10-7
rs58823963 9 9550389 PTPRD* A/C 0.12 0.98 2.69 1.81–3.99 8.81x10-7
CHR = Chromosome; SNP = Single Nucleotide Polymorphism; EA = Effect Allele; RA = Reference Allele
*SNP is on gene; EAF = Effect Allele Frequency for Controls; OR = Odds Ratio; CI = Confidence Interval; P = p-value from logistic regression; Logistic
regression models were adjusted for age at ascertainment, BMI (continuous), parity continuous) and 4 genetic ancestry components (continuous)
doi:10.1371/journal.pone.0141647.t003
Fig 4. Regional association plots showing–log10(p-values) against base-pair position for African American (AA) women considering grade 0 vs.
1–3 analyses.
doi:10.1371/journal.pone.0141647.g004
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were comparable to the original models. Correlation plots for analyses with and without adjust-
ment for hysterectomy for top hits are shown in S3 Fig. Additionally, performing analyses for the
top SNPs by strata of hysterectomy status provided comparable results with high R2 estimates
(S8 Fig). Finally, we provide effect estimates for six previously reported genome-wide significant
SNPs [19]. We found suggestive evidence for rs1810636 (OR: 1.29; 95% CI: 0.99–1.69; P = 0.06)
in our AA analyses when analyzing grade 0 vs. grades 2–3 POP. The magnitude and direction of
OR for other SNPs were not consistent across ethnicities and close to the null (Table 5).
Discussion
We observed several potential loci which may be associated with POP among AA and HP
women in the Women’s Health Initiative. While strong associations were observed, these
Fig 5. Regional association plots showing–log10(p-values) against base-pair position for Hispanic
(HP) women considering grade 0 vs. 1–3 analyses.
doi:10.1371/journal.pone.0141647.g005
Table 4. Meta-analysis of SNPs from race specific analyses using theWomen’s Health Initiative.
SNP CHR BP Gene EA/RA AA HP Meta-analysis
EAF Info OR P EAF Info OR P OR P I2
Any POP rs11243354 7 154379234 DPP6* C/T 0.45 0.96 1.36 1.72x10-05 0.20 0.94 1.39 9.54x10-03 1.36 5.22x10-7 0
POP rs740494 1 230644927 PGBD5 G/C 0.12 0.80 2.29 8.60x10-05 0.12 0.80 2.02 2.77x10-03 2.17 8.61x10-7 0
Grades 2–3 rs2209875 9 91813461 SHC3 A/G 0.31 0.99 0.64 1.44x10-03 0.48 0.99 0.55 1.40x10-04 0.60 9.28x10-7 0
CHR = Chromosome; SNP = Single Nucleotide Polymorphism; EA = Effect Allele; RA = Reference Allele
*SNP is on gene; EAF = Effect Allele Frequency for Controls; OR = Odds Ratio; CI = Confidence Interval; AA = African American; HP = Hispanic; Logistic
regression models were adjusted for age at ascertainment, BMI (continuous), parity continuous) and 4 genetic ancestry components (continuous)
doi:10.1371/journal.pone.0141647.t004
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associations were not genome-wide significant. However, we note that several of the associa-
tions were consistent with regards to the direction and magnitude across populations. Addi-
tionally, the magnitudes of associations were generally larger for the grade 0 vs 2–3 analyses
than for grade 0 vs. 1–3 analyses. This is consistent with the hypothesis that women with a
strong genetic risk for POP are more likely to have advanced POP. The strongest observed
associations (smallest p-values) for grade 0 vs 2&3 were in both AAs (CPE gene) and HPs
(nearby AL132709.5,MIR370 and RTL1). Meta-analysis of grade 0 vs. 1–3 analysis identified a
SNP in the gene DPP6 had the strongest association with POP.
CPE is a secretory protein involved in the biosynthesis of peptide hormones and neurotrans-
mitters, such as insulin, involved in energy balance, nutrient partition, and satiety [33]. Animal
model studies have associated mutations in the CPE gene with obesity, diabetes, infertility, and
hyperinsulinemia in mice [34;35]. Although, there is no known direct relationship between
CPE and POP, high BMI is an important risk factor for POP. Furthermore, metabolic syn-
drome, which involves obesity, cardiac risk factors, insulin resistance, systemic inflammation,
atherogenic dyslipidemia and endothelial dysfunction, has associated with multiple urologic
conditions including POP [36]. The strongest associated variant in HPs was not in a gene, but
was located near AL132709.5,MIR370, and RTL1. There is no established relationship between
these genes and POP or POP-related phenotypes. Another locus surrounding SNP rs7187140,
identified in the AA grade 0 vs. 2–3 analysis, is also noteworthy in relation to POP. Although
the SNP is intergenic, it is within 60 kb of the smooth muscle myosin heavy chain 11 (MYH11)
gene. In a small gene expression study in tissue from anterior vaginal walls, Bortolini and col-
leagues showedMYH11 gene expression was down regulated in pre-menopausal women with
POP compared with premenopausal women without POP [37].
Meta-analyses identified strong associations on the gene DPP6. The direction of the associa-
tion for the most statistically significant SNP (rs11273354) was consistent across AAs and HPs.
The SNP was also common in both populations (minor allele frequency>0.05). DPP6 is a sin-
gle transmembrane protein an important protein for voltage-gated ion channels in determining
cellular excitability. To date, there have not been any reports of an association of DPP6 with
POP or any POP-related phenotypes. It is of interest that base-pair variation in the SNP
rs11273354 alters binding motif of transcription factors containing the forkhead box D1
Table 5. ORs andminor allele frequencies of six statistically significant SNPs evaluated by *Allen-Brady et al. in current analyses evaluating
Grade 0 vs. 2–3 POP analyses using data from theWomen’s Health Initiative.
WHI-AA Grade 0 vs. 2–3
Analysis
WHI-HP Grade 0 vs. 2–3
Analysis
1000G Phase 3 Samples**
Marker Location Gene P OR MAF P OR MAF MAF
Controls Controls CEU/YRI/ASW/MXL
rs1455311 4q21.21 Intergenic 0.94 1.02 0.08 0.97 0.99 0.12 0.19/0.03/0.11/0.09
rs1036819 8q24.22 ZFAT 0.62 0.88 0.07 0.39 1.22 0.11 0.12/0.06/0.02/0.16
rs430794 9q22.2 Intergenic 0.49 1.09 0.46 0.27 1.18 0.36 0.28/0.49/0.45/0.38
rs8027714 15q11.2 Intergenic 0.35 0.87 0.28 NA NA NA 0.04/0.31/0.29/0.02
rs1810636 20p13 Intergenic 0.06 1.29 0.29 0.14 0.80 0.38 0.34/0.26/0.30/0.22
rs2236479 21q22.3 COL18A1 0.99 0.99 0.49 0.74 1.05 0.38 0.32/0.53/0.48/0.34
MAF = Minor allele frequency; OR = odds ratio; 1000G = 1000 Genomes Project; NA = Not applicable as SNP was not assessed due to low minor allele
frequency
*Refers to SNPs published in Table 2 of article by Allen-Brady et al. [19]
**Source for reference population minor allele frequencies: http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/
doi:10.1371/journal.pone.0141647.t005
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(FOXD1) gene [38]. Evaluation of expression quantitative trait loci (eQTL) using the GTEx
portal [39] showed several SNPs in the DPP6 gene were associated with subcutaneous adipos-
ity, potentially suggesting indirect ties between obesity and POP which is not fully understood.
DPP6 has been associated with pancreatic cancer, tardive dyskinesia and amyotrophic lateral
sclerosis in prior studies [40–44]. The piggyBac transposable element derived 5 (PGBD5) gene,
identified in the grade 0 vs. 2–3 meta-analysis may also be a potential gene of interest in rela-
tion to POP. Although there have been no direct ties between PGBD5 and POP in the literature,
it is of interest that several eQTL have been shown to alter expression of this gene in the tibial
nerve [39]. The tibial nerve originates from the same lumbar and sacral nerves (L5 through S3)
which also innervate the pelvic floor [45]. Studies suggest that neuro-modulation through per-
cutaneous or posterior tibial nerve stimulation, may be beneficial in alleviating symptoms asso-
ciated with pelvic floor disorders including fecal and urinary incontinence [46–48].
We took several measures to ensure the validity of the observed associations. In the
WHI-HT a large proportion of women had undergone hysterectomy prior to study enrollment,
with no information on the indication for hysterectomy. Considering that POP is the 3rd lead-
ing indication for hysterectomy in women, it is then possible that some women might have had
POP previously but was not detected at baseline. At the same time, women without a uterus
can still develop other forms of prolapse such as rectocele and cystocele, as was the case during
follow-up. To address this concern we performed analyses adjusting for hysterectomy and by
strata of hysterectomy for our top hits and showed that these estimates were highly correlated.
Therefore, bias introduced by hysterectomy status is not a likely explanation for associations
observed in this study. Additionally, we compared the magnitudes of associations for our top
hits in the any POP and moderate-severe POP analyses to show that not only were these associ-
ations in the same direction, but that the magnitude of effect estimates were larger for analyses
considering moderate-severe POP than any POP. Effect estimates in the any POP analyses
were likely driven by moderate-severe POP cases. One additional advantage of using the
WHI-HT dataset is that information on important risk factors for POP was collected uniformly
across all patients. In our analyses we adjusted for age, BMI and parity as these have been
shown to be important risk factors for POP. Ideally, adjustment for mode of delivery would
have provided for a more robust analysis, however, the WHI-HT did not collect this
information.
We were not able to replicate the associations observed in a previously published GWAS by
Allen-Brady et al., in a EA population with 115 cases and 2,976 controls [19]. Although cases
were well-characterized, the study utilized general-population controls for whom the pheno-
type status was not verified. The study identified associations in six chromosomal regions
4q21, 8q24, 9q22, 15q11, 20p13, and 21q22. Two of the strongest associated SNPs were located
within a gene: rs2236479 (COL18A1) and rs1036819 (ZFAT). The odds ratios we observed for
these loci were close to the null and corresponding P values were>0.05. Potential reasons we
were unable to replicate these findings are that genetic variants for POP may differ across
racial/ethnic populations or power, as the minor allele frequency for these previously associ-
ated variants varies significantly across geographic populations.
To our knowledge, this is the second GWAS that evaluates POP risk and the first GWAS in
AA and HP women. Majority of other genetic investigations evaluating POP risk have been
limited to relatively smaller candidate gene studies that primarily focused on women of Euro-
pean or Asian descent [21]. The lack of GWAS evaluating POP, especially in minority popula-
tions and the lack of replication of candidate gene signals across existing studies are likely due
to several factors and barriers, as highlighted by Wu et al. [49]. First, POP is a difficult pheno-
type to characterize as it involves a specialized pelvic exam and is rarely evaluated in research
studies as routine practice. Secondly, a well conducted genetic epidemiologic study also equally
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rests on proper characterization of controls to reduce outcome misclassification. Prevalence of
POP increases with age, especially after menopause and is highly prevalent in this population.
The timing of control classification is thus of crucial importance, with ideal preference for
including older post-menopausal women with no POP over younger pre-menopausal women
to potentially reduce outcome misclassification.
Using the WHI-HT data allowed us to overcome these two barriers to a certain degree to
conduct the study at hand. TheWHI-HT used centrally validated standardized procedures per-
formed by trained medical staff to collect information on POP at baseline and at up to
10-annual visits per individual (all of whom were post-menopausal). This not only allowed us
to properly identify POP cases who developed POP during follow-up visits, but also allowed us
to classify women as controls considering multiple visits, when possible. Even though is a
marked improvement over previous studies that have investigated POP, there is likely some
degree of misclassification in our study as well. While information on POP was available for
multiple visits, the loss-to-follow-up rate in the WHI-HT was extremely high. Consequently,
for controls identified at baseline that were lost to follow-up, we could not determine POP sta-
tus through time. For majority of the cases who had two or more assessments of POP (612 AA
POP cases and 498 HP POP cases), POP could be verified at two or more visits for 70% of
these AA POP cases and 80% of these HP POP cases. For some women POP grade fluctuated
between visits; this speaks to a degree of subjectivity in POP measurement even when using
standardized procedures. For women with information on POP for multiple visits, we noted
the visit at the first ascertainment of POP when considering any POP and the first ascertain-
ment of grade 2 or higher POP when considering moderate/severe POP. It should also be
noted that POP was measured in the supine lithotomy position in the WHI-HT, and therefore,
the maximal extant of prolapse was likely underestimated compared with a semi-upright or
upright position of assessment, which is ideal for determining the maximum extent of
prolapse.
Thirdly, resources for large scale genetic investigations for phenotypes such as POP are
extremely limited, making replication of findings a difficult task to achieve. This especially
rings true for investigation in minority populations such as AAs and HPs, who have historically
been under-represented in medical research in general. We were unable to replicate our find-
ings in an independent cohort of AA and HP women, and stress the need for an independent
replication of our findings. To address this, we performed trans-ethnic replication across AAs
and HPs. Although we have a strong sample size of 2,701 women, the number of women with
POP was limited (any POP: n = 1,382). However, a small proportion of women (n = 317) had
grades 2–3 POP and even fewer women had POP which protruded beyond the introitus. This
resulted in our analysis being underpowered to detect smaller associations. Given the highly
stringent p-value threshold due to multiple testing, the possibility that our findings are due to
chance alone cannot be ruled out. Additionally, since we had only two datasets for meta-analy-
sis, we resorted to using a fixed effects meta-analysis framework, instead of newer trans-ethnic
meta-analysis techniques such as new-random-effects model [31] or MANTRA [32]. Both
these methods have been shown to boost power especially in scenarios with allele frequency
differences and/or extreme allelic heterogeneity [50]. Simulations of a considerably larger num-
ber of studies (N = 30) have demonstrated considerably improved power for these techniques,
however, these techniques are also underpowered as the number of meta-analysis studies
decrease (N = 10) in the presence of effect-size heterogeneity [50]. The added benefit from uti-
lizing these techniques when the number of studies is small (N = 2) is not clear. By design our
meta-analysis is most sensitive to identifying associations for variants with similar allele fre-
quencies and effect estimates across populations. Considering lower prevalence of POP in AA
women compared with HP women it is likely that there may be ancestry specific loci which we
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were not able to detect through this meta-analytic technique. Future meta-analysis of a greater
number of studies with diverse populations, coupled with meta-analysis techniques designed to
leverage heterogeneity associated with between population differences may provide insight
into these loci.
To our knowledge, the WHI-HT data is the only resource available which has validated
detailed information on POP and simultaneous availability of genetic data. The surge of inter-
est in utilizing Electronic medical record (EMR) databases for research investigation provides
future hope for replicating these results. However, constructing a well characterized set of cases
and controls requires building algorithms that can identify cases and controls with a high
degree of sensitivity and specificity, respectively. To this end, our group is currently in the pro-
cess of developing algorithms using EMR data from the BioVU DNA repository at Vanderbilt
University, which we hope to apply in larger EMR database networks with available GWAS
data for replication in the future.
Little is known about POP pathophysiology or genetic risk factors, particularly among AA
and HP women. Our study is the first POP GWAS in minority women. Our findings suggest
that common germ-line variations may contribute to increased risk for POP among AAs and
HPs; however, further research with larger minority sample sizes is necessary to validate our
study findings.
Supporting Information
S1 Fig. Multidimensional Scaling (MDS) Components plot of WHI POP cases and controls
compared with HAPMAP reference e populations.MDS axes for African Americans and
Hispanics were plotted with MDS1 on the y-axis and MDS2 on the x-axis. Values were color
coded according to self-reported race among cases and controls and compared to HAPMAP
reference populations. Populations are labeled in the legend within the figure.
(TIF)
S2 Fig. Manhattan plot of single SNP association analyses considering grade 0 vs. grade
1–3 POP for African American (AA) women from the Women’s Health Initiative. Logistic
regression models were adjusted for age at ascertainment (continuous), body mass index (con-
tinuous), parity (continuous) and genetic ancestry components (continuous). X-axis: base-pair
position; Y-axis: -log10(p-values).
(TIF)
S3 Fig. Manhattan plot of single SNP association analyses considering grade 0 vs. grade
1–3 POP for Hispanic (HP) women from the Women’s Health Initiative. Logistic regression
models were adjusted for age at ascertainment (continuous), body mass index (continuous),
parity (continuous) and genetic ancestry components (continuous). X-axis: base-pair position;
Y-axis: -log10(p-values).
(TIF)
S4 Fig. Manhattan plot of single SNP association analyses considering grade 0 vs. grade
2–3 POP for African American (AA) women from the Women’s Health Initiative. Logistic
regression models were adjusted for age at ascertainment (continuous), body mass index (con-
tinuous), parity (continuous) and genetic ancestry components (continuous). X-axis: base-pair
position; Y-axis: -log10(p-values).
(TIF)
S5 Fig. Manhattan plot of single SNP association analyses considering grade 0 vs. grade
2–3 POP for Hispanic (HP) women from the Women’s Health Initiative. Logistic regression
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models were adjusted for age at ascertainment (continuous), body mass index (continuous),
parity (continuous) and genetic ancestry components (continuous). X-axis: base-pair position;
Y-axis: -log10(p-values).
(TIF)
S6 Fig. Compares log(OR) estimates from single SNP association analyses from grade 0 vs.
any POP models to grade 0 vs. moderate/severe POP models. This figure compares beta-esti-
mates of top hits (p<10–5) originating from either any POP or moderate/severe POP models
where all models were adjusted for age, BMI, parity and ancestry components. X-axis and Y-
axis represents natural log transformed odds ratios from any POP and moderate/severe POP
models, respectively. left plot: AAs; right plot: HPs.
(TIF)
S7 Fig. Summary of log(OR) of single SNP association analyses adjusted for hysterectomy
compared to no adjustment for hysterectomy. This figure compares beta-estimates of top
hits (p< 10−5) from models adjusted for age, BMI, parity and ancestry components to models
adjusted for hysterectomy in addition to the aforementioned variables. Original refers to betas
from models adjusted for age, BMI, parity and ancestry components; Hysterectomy adjusted
refers to betas from models adjusted for hysterectomy status in addition to factors in the origi-
nal models.
(TIF)
S8 Fig. Summary of log(OR) estimates from single SNP association analyses by strata of
hysterectomy status. This figure compares beta-estimates of top hits (p< 10−5) from models
adjusted for age, BMI, parity and ancestry components in women with and without a hysterec-
tomy at baseline. X-axis and Y-axis represents natural log transformed odds ratios from analy-
ses in women without hysterectomy and women with hysterectomy, respectively. Top 2 plots
are for AAs (Any POP and moderate/severe POP, left to right). Bottom two plots are for HPs
(Any POP and moderate/severe POP, left to right).
(TIF)
S1 Table. Associations between key risk factors for any pelvic organ prolapse and grades
2–3 pelvic organ prolapse in the WHI Hormone Therapy trial. The following table presents
the associations between key risk factors in relation to any POP (grades 1–3) and severe/mod-
erate POP (grades 2–3).
(DOCX)
S2 Table. Results from meta-analysis of Grade 0 vs. Grade 1–3 POP across African Ameri-
can (AA) and Hispanic (HP) Women from the Women’s Health Initiative. The following
table presents results on single nucleotide polymorphisms (SNPs) associated with Grade 1–3
prolapse, which had p< 0.00001 in the fixed effects meta-analysis. Results from random-
effects models and Heterogeneity Scores (I2) are also presented.
(DOCX)
S3 Table. Results from meta-analysis of Grade 0 vs. Grade 2–3 POP across African Ameri-
can (AA) and Hispanic (HP) women from the Women’s Health Initiative. The following
table presents results on single nucleotide polymorphisms (SNPs) associated with Grade 2–3
prolapse, which had p< 0.00001 in the fixed effects meta-analysis. Results from random-
effects models and Heterogeneity Scores (I2) are also presented.
(DOCX)
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